StockData
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. (VIR) shareholders

VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3028% below fair value
$9.25−0.33 (-3.44%)

Close on Nov 17, 2026Market cap $1.57BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
86.6%
147M of 169M shares
Institutional holders
237
33 new, 43 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
0 buys · 33 sales
Net sold $8.15M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.20,905,68112.40%13G (passive) amendmentSep 30, 2026
Robert Nelsen
Joint filing with Keith Crandell (7.10%), Clinton Bybee (7.00%) and 5 more
12,508,0297.30%13D (active) amendmentNov 4, 2026
Vanguard Portfolio Management11,554,3776.85%13G (passive) amendmentJun 30, 2026
SoftBank Vision Fund (AIV M1) L.P.
Joint filing with SB Investment Advisers (UK) Limited (6.50%), SVF Endurance (Cayman) Limited (6.50%)
10,948,0936.50%13G (passive) amendmentMar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of VIRValueChange% of portfolio
BlackRock, Inc.20,678,28312.22%$210.71M+2,679,9540.00%
ARCH Venture Management, LLC12,694,1637.50%$129.35M−222,50011.76%
Vanguard Portfolio Management LLC11,495,2156.79%$117.14M+2,279,6380.01%
Sb Investment Advisers (Uk) Ltd10,948,0936.47%$111.56M–1.46%
State Street Corp9,964,1515.89%$101.53M+2,823,0570.00%
GSK plc8,550,9545.05%$87.13M–14.47%
Vanguard Capital Management LLC6,388,7753.78%$65.10M+1,006,6720.00%
Point72 Asset Management, L.P.5,666,8213.35%$57.74M+3,714,5870.06%
Geode Capital Management, LLC3,348,3661.98%$34.12M+690,5230.00%
Dimensional Fund Advisors LP3,119,4211.84%$31.79M+539,7430.01%
ADAR1 Capital Management, LLC2,456,6771.45%$25.03M−288,0371.15%
Goldman Sachs Group Inc2,365,2191.40%$24.10M−885,0080.00%
FMR LLC2,318,2941.37%$23.62M+246,4460.00%
Morgan Stanley2,211,0771.31%$22.53M−643,1280.00%
Nuveen, LLC1,982,9421.17%$20.21M+963,9780.00%
Pictet Asset Management Holding SA1,953,3161.15%$19.90M+472,4880.02%
Boxer Capital Management, LLC1,866,0001.10%$19.01M–1.43%
Northern Trust Corp1,432,1650.85%$14.59M+446,7300.00%
Hudson Bay Capital Management LP1,364,0000.81%$13.90M−105,5100.04%
GordonMD Global Investments LP1,353,5520.80%$13.79M−165,0006.67%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026237147M86.6%33 / 9377 / 4322M16M
Q1 2026252140M82.8%69 / 11841 / 3052M15M
Q4 2025218116M68.5%33 / 6679 / 2619M11M
Q3 2025213107M63.5%28 / 6082 / 266M10M
Q2 2025213111M65.9%23 / 8261 / 4224M6M
Q1 202523393M55.1%53 / 7470 / 2615M10M
Q4 202420889M52.5%42 / 6870 / 2912M10M
Q3 202419789M52.4%22 / 7767 / 3823M7M
Q2 202421589M52.7%34 / 7473 / 2510M15M
Q1 202420994M55.8%31 / 7267 / 2710M6M
Q4 202320691M53.5%28 / 6874 / 3311M9M
Q3 202321489M52.3%40 / 9652 / 5215M17M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

237 funds held VIR in Q2 2026, 71% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of VIRValue% of fundAs of
iShares Core S&P Small-Cap ETF7,317,3954.32%$74.56M0.07%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF4,945,4852.92%$50.39M0.47%Jun 30, 2026
Vanguard Total Stock Market Index Fund4,846,9482.86%$49.39M0.00%Jun 30, 2026
Vanguard Small-Cap Index Fund3,476,6692.05%$35.43M0.02%Jun 30, 2026
iShares Russell 2000 ETF3,155,0761.86%$32.15M0.04%Jun 30, 2026
Vanguard Small-Cap Growth Index Fund1,996,6251.18%$20.35M0.04%Jun 30, 2026
Vanguard Strategic Equity Fund1,762,4121.04%$17.96M0.15%Jun 30, 2026
Vanguard Extended Market Index Fund1,398,4830.83%$14.25M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund1,343,7510.79%$11.64M0.03%Jul 31, 2026
iShares Russell 2000 Value ETF1,150,9970.68%$11.73M0.08%Jun 30, 2026
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF1,114,3010.66%$11.35M0.07%Jun 30, 2026
iShares Biotechnology ETF949,1580.56%$9.67M0.11%Jun 30, 2026
Nuveen Quant Small Cap Equity Fund892,3200.53%$7.73M0.19%Jul 31, 2026
Vanguard Strategic Small-Cap Equity Fund868,7920.51%$8.85M0.28%Jun 30, 2026
Vanguard Tax-Managed Small-Cap Fund677,3730.40%$6.90M0.06%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Backer Marianne DePresident and CEO, Director1,001,2630.59%Apr 30, 2026
Aziz SawafEVP, Chief Financial Officer75,0000.04%Nov 16, 2026
Brent SabatiniSVP, Chief Accounting Officer111,9020.07%Nov 16, 2026
Verneuil Vanina deEVP, General Counsel, Corp Sec110,1930.07%Nov 4, 2026
Jason O'ByrneEVP & Chief Financial Officer162,6150.10%Mar 23, 2026
Mark EisnerEVP and Chief Medical Officer154,0240.09%Feb 26, 2026
Ann M. HanlyEVP & Chief Technology Officer117,9130.07%Feb 25, 2025
Suzanne Louise TopalianDirector12,7310.01%Oct 28, 2026
Robert J. MoreDirector558,5730.33%Aug 12, 2026
Timothy CoughlinDirector0–Jun 10, 2026
Janet NapolitanoDirector21,2160.01%Jun 2, 2026
Jeffrey S. HatfieldDirector39,8060.02%May 28, 2026
Norbert W. BischofbergerDirector32,0000.02%May 28, 2026
Charles Elliott SigalDirector49,8060.03%May 28, 2026
Ramy FaridDirector32,0000.02%May 28, 2026
Vicki L. SatoDirector1,078,3910.64%May 4, 2026
Saira RamasastryDirector22,6190.01%Jun 2, 2025
George A. ScangosDirector1,849,9691.09%Feb 25, 2025
Endurance (Cayman) Ltd SVF10% owner13,728,9248.11%Dec 3, 2025
Vision Fund (Aiv M1) L.P. Softbank10% owner13,920,7788.23%Dec 3, 2025
Investment Advisers (Uk) Ltd Sb10% owner14,598,5368.63%Dec 3, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Aziz Sawaf
EVP, Chief Financial Officer
Nov 15, 2026Award+75,000––75,000
Brent Sabatini
SVP, Chief Accounting Officer
Nov 15, 2026Award+50,000––111,902
Verneuil Vanina de
EVP, General Counsel, Corp Sec
Nov 3, 2026Sale(10b5-1 plan)−2,407$11.10$26.72K110,193
Verneuil Vanina de
EVP, General Counsel, Corp Sec
Nov 2, 2026Sale(10b5-1 plan)−1,343$11.33$15.22K112,600
Suzanne Louise Topalian
Director
Oct 27, 2026Award+4,731––12,731
Suzanne Louise Topalian
Director
Oct 27, 2026Award+8,000––8,000
Robert J. More
Director
Aug 11, 2026Other−8,000––40,656
Robert J. More
Director
Aug 11, 2026Other+8,000––517,917
Timothy Coughlin
Director
Jun 9, 2026Award+8,000––8,000
Timothy Coughlin
Director
Jun 9, 2026Award+8,000––16,000
Brent Sabatini
SVP, Chief Accounting Officer
Jun 1, 2026Sale(10b5-1 plan)−379$9.45$3.58K61,902
Janet Napolitano
Director
Jun 1, 2026Sale(10b5-1 plan)−3,200$9.45$30.24K21,216
Jeffrey S. Hatfield
Director
May 27, 2026Award+8,000––39,806
Ramy Farid
Director
May 27, 2026Award+8,000––32,000
Charles Elliott Sigal
Director
May 27, 2026Award+8,000––39,806
Janet Napolitano
Director
May 27, 2026Award+8,000––24,416
Robert J. More
Director
May 27, 2026Award+8,000––48,656
Norbert W. Bischofberger
Director
May 27, 2026Award+8,000––21,333
Vicki L. Sato
Director
May 1, 2026Sale(10b5-1 plan)−22,000$10.05$221.10K1,078,391
Backer Marianne De
President and CEO, Director
Apr 29, 2026Other+233,532––286,650
Backer Marianne De
President and CEO, Director
Apr 29, 2026Other−233,532––714,613
Backer Marianne De
President and CEO, Director
Apr 6, 2026Sale(10b5-1 plan)−72,559$9.16$664.64K948,145
Vicki L. Sato
Director
Apr 1, 2026Sale(10b5-1 plan)−22,000$9.07$199.54K1,100,391
Brent Sabatini
SVP, Chief Accounting Officer
Mar 23, 2026Sale(10b5-1 plan)−7,711$9.12$70.32K61,902
Jason O'Byrne
EVP & Chief Financial Officer
Mar 20, 2026Other+2,500––2,500
Jason O'Byrne
EVP & Chief Financial Officer
Mar 20, 2026Other−2,500––160,115
Vicki L. Sato
Director
Mar 2, 2026Sale(10b5-1 plan)−21,800$9.50$207.10K1,122,591
Vicki L. Sato
Director
Mar 2, 2026Sale(10b5-1 plan)−200$9.98$2.00K1,122,391
Mark Eisner
EVP and Chief Medical Officer
Feb 25, 2026Sale(10b5-1 plan)−1,889$9.82$18.55K154,024
Verneuil Vanina de
EVP, General Counsel, Corp Sec
Feb 25, 2026Sale(10b5-1 plan)−13,700$9.82$134.53K112,982
Mark Eisner
EVP and Chief Medical Officer
Feb 24, 2026Sale(10b5-1 plan)−1,616$9.53$15.40K155,913
Verneuil Vanina de
EVP, General Counsel, Corp Sec
Feb 24, 2026Sale(10b5-1 plan)−3,117$9.53$29.71K126,682
Jason O'Byrne
EVP & Chief Financial Officer
Feb 24, 2026Sale(10b5-1 plan)−1,634$9.53$15.57K162,615
Backer Marianne De
Chief Executive Officer, Director
Feb 24, 2026Sale(10b5-1 plan)−14,762$9.53$140.68K1,020,704
Brent Sabatini
SVP, Chief Accounting Officer
Feb 24, 2026Sale(10b5-1 plan)−1,430$9.53$13.63K69,613
Vicki L. Sato
Director
Feb 24, 2026Sale(10b5-1 plan)−200$10.26$2.05K1,144,391
Vicki L. Sato
Director
Feb 24, 2026Sale(10b5-1 plan)−42,177$9.75$411.23K1,144,591
Vicki L. Sato
Director
Feb 24, 2026Option exercise+42,377$1.49$63.14K1,186,768
Mark Eisner
EVP and Chief Medical Officer
Feb 23, 2026Sale(10b5-1 plan)−2,089$7.45$15.56K157,529
Jason O'Byrne
EVP & Chief Financial Officer
Feb 23, 2026Sale(10b5-1 plan)−2,089$7.45$15.56K164,249
Brent Sabatini
SVP, Chief Accounting Officer
Feb 23, 2026Sale(10b5-1 plan)−1,829$7.45$13.63K71,043
Verneuil Vanina de
EVP, General Counsel, Corp Sec
Feb 23, 2026Sale(10b5-1 plan)−4,445$7.45$33.12K129,799
Backer Marianne De
Chief Executive Officer, Director
Feb 23, 2026Sale(10b5-1 plan)−19,039$7.45$141.84K1,035,466
Mark Eisner
EVP and Chief Medical Officer
Feb 22, 2026Award+55,000––159,618
Jason O'Byrne
EVP & Chief Financial Officer
Feb 22, 2026Award+55,000––166,338
Brent Sabatini
SVP, Chief Accounting Officer
Feb 22, 2026Award+25,000––72,872
Verneuil Vanina de
EVP, General Counsel, Corp Sec
Feb 22, 2026Award+55,000––134,244
Backer Marianne De
Chief Executive Officer, Director
Feb 22, 2026Award+285,000––1,054,505
Brent Sabatini
SVP, Chief Accounting Officer
Feb 13, 2026Sale(10b5-1 plan)−1,530$7.79$11.92K47,872
Vicki L. Sato
Director
Feb 2, 2026Sale(10b5-1 plan)−22,000$7.71$169.62K1,144,391
Vicki L. Sato
Director
Jan 2, 2026Sale(10b5-1 plan)−22,000$5.93$130.46K1,166,391
Endurance (Cayman) Ltd SVF
10% owner
Dec 1, 2025Sale(10b5-1 plan)−191,854$5.98$1.15M13,728,924
Vicki L. Sato
Director
Dec 1, 2025Sale(10b5-1 plan)−22,000$6.00$132.00K1,188,391
Vision Fund (Aiv M1) L.P. Softbank
10% owner
Nov 28, 2025Sale(10b5-1 plan)−61,493$6.44$396.01K13,920,778
Vision Fund (Aiv M1) L.P. Softbank
10% owner
Nov 26, 2025Sale(10b5-1 plan)−127,938$6.39$817.52K13,982,271
Endurance (Cayman) Ltd SVF
10% owner
Nov 25, 2025Sale(10b5-1 plan)−235,971$6.38$1.51M14,110,209
Endurance (Cayman) Ltd SVF
10% owner
Nov 24, 2025Sale(10b5-1 plan)−227,803$6.15$1.40M14,346,180
Jason O'Byrne
EVP & Chief Financial Officer
Nov 17, 2025Sale(10b5-1 plan)−6,799$5.56$37.80K110,701
Verneuil Vanina de
EVP, General Counsel, Corp Sec
Nov 5, 2025Sale(10b5-1 plan)−2,385$5.16$12.31K78,210
Vicki L. Sato
Director
Nov 3, 2025Sale(10b5-1 plan)−22,000$5.64$124.08K1,210,391

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
12.02%
17M shares short
Days to cover
11.9
At 1M shares a day
Change since last report
+3.9%
From 16M shares
Short volume, 20 days
52.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Vir Biotechnology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 84,198 shares on Oct 6, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Verneuil Vanina de
Officer
Nov 3, 20262,407$26.72KNov 3, 2026Restricted Stock Vesting
Verneuil Vanina de
Officer
Nov 2, 20261,343$15.22KNov 2, 2026Restricted Stock Vesting
Jason O'Byrne
Former Officer
Sep 17, 202619,357$212.93KSep 17, 2026Restricted Stock Vesting
Jason O'Byrne
Former Officer
Sep 9, 202628,333$315.24KSep 9, 2026Stock Option Exercise
Jason O'Byrne
Former Officer
Aug 25, 202623,148$242.59KAug 25, 2026Stock Option Exercise
Jason O'Byrne
Former Officer
Aug 24, 202614,352$142.12KAug 24, 2026Stock Option Exercise
Jason O'Byrne
Former Officer
Aug 21, 202625,000$245.30KAug 21, 2026Stock Option Exercise
Saira Ramasastry
Former Director
Jun 29, 202616,000$165.14KJun 29, 2026Stock Option Exercise
Janet Napolitano
Director
Jun 1, 20263,200$30.24KJun 1, 2026Restricted Stock Vesting
Brent Sabatini
Officer
Jun 1, 2026379$3.58KJun 1, 2026ESPP Purchase
Mark Eisner
Former Officer
Apr 30, 202688,958$916.27KApr 30, 2026Option Granted - 07/15/2024
Backer Marianne De
Officer, Director
Apr 6, 202672,559$664.34KApr 6, 2026Restricted Stock Vesting
Brent Sabatini
Officer
Mar 23, 20267,711$70.32KMar 23, 2026Restricted Stock Vesting
Vicki L. Sato
Director
Mar 2, 202688,000$799.92KMar 2, 2026Pre-IPO Shares
Mark Eisner
Officer
Feb 25, 20261,889$18.55KFeb 25, 2026Restricted Stock Vesting

See a number that looks wrong?